Gregory K. Edmundson

TL;DR: If true, hypofractionation or HDR regimens for prostate radiotherapy (with appropriate doses) should produce tumor control and late sequelae that are at least as good or even better than currently achieved, with the added possibility that early sequelae may be reduced.

TL;DR: The protocol using C-HDR interstitial brachytherapy as monotherapy for early cancer of the prostate was feasible and well tolerated by 41 patients treated and changes in interfraction prostate volume do not appear to be significant enough to warrant modification of dosimetry for each fraction.

TL;DR: ITP addresses many of the limitations of current permanent prostate brachytherapy and has some advantages over the preplanned technique.

TL;DR: The MammoSite device as discussed by the authors was developed with the goal of making breast-conserving therapy more widely available, by making breast brachytherapy as monotherapy simpler and more accurate.

TL;DR: Pelvic EBRT interdigitated with transrectal ultrasound-guided real-time conformal HDR prostate brachytherapy boost is both a precise dose delivery system and a very effective treatment for unfavorable prostate cancer.